Quick Answer
BriaCell Therapeutics Corp. reported Research And Development Expense of $21.27 million for the year ending 2025.
- BriaCell Therapeutics Corp. showed a decrease of -21.7% in Research And Development Expense from 2024 to 2025.
- This data is from BriaCell Therapeutics Corp.'s annual report (Form 10-K), filed with the SEC on October 16, 2025.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2021: $875.6 thousand | Q1 2022: $1.71 million | Q2 2022: $2.27 million | Q4 2022: $3.26 million | Q1 2023: $3.05 million | Q2 2023: $3.86 million | Q4 2023: $6.86 million | Q1 2024: $8.26 million | Q2 2024: $7.66 million | Q4 2024: $3.67 million | Q1 2025: $5.68 million | Q2 2025: $4.81 million | Q4 2025: $6.68 million.
- Over the full 5 years of available data (2021 to 2025), BriaCell Therapeutics Corp.'s Research And Development Expense has grown by 952.5%.
- Historical annual values: Fiscal year 2025: $21.27 million | Fiscal year 2024: $27.18 million | Fiscal year 2023: $15.34 million | Fiscal year 2022: $8.02 million | Fiscal year 2021: $2.02 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: